Laura Shawver, Silverback

Sil­ver­back files to go pub­lic, po­ten­tial­ly adding to this year's record-high biotech IPO raise

The signs were there: A cou­ple of months ago, Sil­ver­back Ther­a­peu­tics quick­ly pulled in $163 mil­lion in two back-to-back rounds for what CEO Lau­ra Shawver called “an im­por­tant growth phase.” As ex­pect­ed, the Seat­tle-based biotech turned in its S-1 on Tues­day seek­ing a $100 mil­lion IPO.

Sil­ver­back could be one of more than 72 biotech and bio­phar­ma com­pa­nies to hit Wall Street this year, con­tribut­ing to a record raise of over $13 bil­lion. Many up­sized their of­fers, and if Sil­ver­back fol­lows suit, it could stand to raise much more than its $100 mil­lion bid. A cou­ple of weeks ago, Nas­daq head of health­care list­ings Jor­dan Saxe pegged a “fair es­ti­mate” of 75 de­buts and just un­der $14 bil­lion in pro­ceeds to round out the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.